Low fodmap diet
Otherexperimental group consume low fodmap diet
Other names: diet
NCT Number: NCT07467278
This study aimed to evaluate the effects of a Low-FODMAP diet on intestinal permeability, symptom severity, and quality of life in patients with Irritable Bowel Syndrome (IBS). Twenty-four patients diagnosed with IBS according to the Rome IV criteria were randomized to either a Low-FODMAP diet or a traditional diet for four weeks. Stool zonulin family peptides (ZFP), IBS Symptom Severity Score (IBS-SSS), and IBS Quality of Life (IBS-QOL) questionnaires were recorded at baseline and after the dietary intervention. In the Low-FODMAP group, FODMAP-containing foods were gradually reintroduced under dietitian supervision, and assessments were repeated at week 16 to evaluate long-term effects.
Trial opening soon.
Get Notified18 year–65 year
All sexes
Interventional
Not applicable
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits without an identifiable organic cause. Dietary factors and increased intestinal permeability have been proposed as potential mechanisms contributing to symptom development.
The Low-FODMAP diet has been shown to improve IBS symptoms by reducing fermentable carbohydrate intake. However, its effects on intestinal barrier integrity remain unclear.
This prospective randomized single-blind study was conducted at Istanbul Medipol Mega University Hospital between December 2023 and December 2024. Patients aged 18-65 years diagnosed with IBS according to the Rome IV criteria were included. Participants were randomized to follow either a Low-FODMAP diet or a traditional diet for four weeks. Stool zonulin family peptides (ZFP) were measured as a biomarker of intestinal permeability. Symptom severity and quality of life were evaluated using validated IBS-SSS and IBS-QOL questionnaires.
After four weeks, patients in the Low-FODMAP group began a structured reintroduction phase where restricted foods were gradually reintroduced over twelve weeks. Follow-up assessments were performed at week 16 to evaluate long-term outcomes.
The study investigated whether dietary FODMAP restriction could improve intestinal barrier function in addition to reducing symptom severity and improving quality of life in patients with IBS.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Age between 18 and 65 years
Diagnosis of Irritable Bowel Syndrome (IBS) according to Rome IV criteria
Patients presenting to Internal Medicine or Gastroenterology outpatient clinics
Ability to provide written informed consent
Willingness to comply with the assigned dietary intervention and follow-up schedule
Patients who were mostly compliant or fully compliant with the dietary protocol (≥51%)
-
Exclusion criteria
Antibiotic or probiotic use within the previous 2 weeks
History of major abdominal surgery
Active malignancy
Heart failure
Renal failure
Autoimmune disease
Inflammatory bowel disease
Celiac disease
Lactose intolerance
Individuals currently following another dietary regimen
Pregnancy
Poor adherence to diet protocol (<51%)
Failure to submit dietary diaries regularly
Need for antibiotic therapy during the intervention period
experimental group consume low fodmap diet
Other names: diet
dietary interventionlow fodmap diet
Time frame: after started diet 4 weeks later and after modified low fodmap diet 8 weeks later check stool analyse again
We aim to investigate that lox fodmap diet has decreased stool zonulin level and improve leaky gut or not
Contact information is provided by the study sponsor or research team.
Istanbul Medipol University Hospital
Other
The Effect of Low-FODMAP Diet on Leaky Gut ,Symptoms and Quality of Life in Patient With Irritable Bowel Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07716852
Colonic Diseases, Colonic Diseases, Functional
View Trial DetailsNCT07693907
Colonic Diseases, Colonic Diseases, Functional
View Trial DetailsNCT06706778
Abdominal Pain, Abdominal Pain/ Discomfort
New Haven, Connecticut, United States
View Trial DetailsNCT07676136
Abdominal Pain, Colonic Diseases
Stanford, California, United States
View Trial Details